Conclusions Prostate tumors of AAM manifest a unique immune repertoire and have significant enrichment of pro-inflammatory immune pathways that are associated with poorer outcomes. Observed immune-oncologic differences can aide in a genomically adaptive approach to treating PCa in AAM. PMID: 33037017 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: UroCAD could be a robust urothelial carcinoma diagnostic method with improved sensitivity and similar specificity as compared with cytology tests. It may be used as a noninvasive approach for diagnosis and recurrence surveillance in urothelial carcinoma prior to the use of cystoscopy, which would largely reduce the burden on patients. PMID: 33037018 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Authors: de Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GML, Robinson K, Hunt M, Healy C, Chan A, Looi YH, Rodrigues C, Rohr UP, Walther C, Pazdur R Abstract In 2019, the FDA Oncology Center of Excellence (OCE) launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, review, and regulatory action for high-impact clinically significant...
CONCLUSIONS: This first-in-human study demonstrates the tolerability, safety, and encouraging efficacy of CD19-PD-1/CD28-CART in PD-L1+ large B-cell lymphoma. PMID: 33028589 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: The newly developed and validated NGS-based multigene assay can predict the distant recurrence risk in ER-positive, HER2-negative breast cancer. PMID: 33028590 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: Hypovascular cellular habitats derived from multiparametric physiologic MRIs may be useful predictors of clinical outcomes in patients with post-treatment glioblastoma. PMID: 33028594 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Conclusion These preclinical studies indicate that osimertinib can achieve significant exposure in the brain compared with the other EGFR-TKIs tested and supports the ongoing clinical evaluation of osimertinib for the treatment of EGFRm brain metastasis. This work also demonstrates the link between low in-vitro transporter efflux ratios and increased brain penetrance in-vivo supporting the use of in-vitro transporter assays as an early screen in drug discovery. PMID: 33028591 [PubMed - as supplied...
CONCLUSIONS: Plasma assay of novel CRC-associated MDMs can reliably detect primary CRC and distantly recurrent CRC with promising accuracy. PMID: 33028593 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: DDIR positivity does not predict improved response following oxaliplatin treatment in CRC. However, data presented here suggests the potential of the DDIR assay in identifying immune-rich tumours that may benefit from immune checkpoint blockade, beyond current use of MSI status. PMID: 33028592 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: In the context of SBRT+P, TMC independently correlates with OS. SBRT impacts intratumoral immune gene expression associated with TMC. Randomized trials are needed to validate these findings. PMID: 33028595 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: This study demonstrates that germline mutation carrier status in PDAC is associated with longer OS compared to non-carriers. Further research into tumor biology and response to platinum-based chemotherapy in germline mutation carriers with PDAC are needed to better understand the association with longer OS. PMID: 33028596 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Authors: Klempner SJ, Upadhyay V, Chao J Abstract In an annotated series of gastroesophageal adenocarcinomas differences in PD-L1 expression and TMB occur between both paired contemporaneous primary and metastatic biopsies and pre/post-treatment samples. This work has implications for optimizing patient selection, serial testing, need for mechanistic understanding, and may underlie variable responses to checkpoint inhibitors in gastroesophageal cancers. PMID: 33023951 [PubMed - as...
CONCLUSIONS: Low relative lesion volume at baseline mpMRI was predictive of pathologic response. A subset of patients had limited response. Selection of patients based on these metrics may improve outcomes in high-risk disease. PMID: 33023952 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: Our findings support forward translational relevance of transcriptional subtypes, where further exploration therein may improve lung adenocarcinoma treatment. PMID: 33023953 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: Interpreting the tumour-immune interface to predict ICI efficacy remains challenging. WGTA allows for identification of multiple biomarkers simultaneously that in combination may help to identify responders, particularly in the context of a heterogeneous population of advanced and previously treated cancers, thus precluding tumour type-specific testing. PMID: 33020056 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: BRCA-related DNA repair deficiency and suppressed tumor immune responses may be clinically relevant predictors of endocrine therapy complementing treatment options in subgroups of hormone-sensitive early breast cancer. PMID: 33008814 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSION: MYC rearrangement is associated with high disease burden and is an independent adverse prognostic factor in newly diagnosed MM. PMID: 33008815 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Authors: Cirella A, Berraondo P, Di Trani CA, Melero I Abstract IL-12 is a very potent cancer immunotherapy agent but is difficult to harness safely if given systemically. Local gene-transfer aims to confine the effects of IL-12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticled messenger RNA achieves IL-12 expression and efficacy in mouse models, opening the way to an ongoing trial. PMID: 33004432 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Authors: PMID: 33004470 [PubMed - in process] (Source: Clinical Cancer Research)
Authors: Marmarelis ME, Bauml JM Abstract The APOLLO investigators showed that NGS of cerebrospinal fluid can reveal molecular alterations - how should this affect our management approach? PMID: 32998958 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου